Eledon Shares Tumble 51% Amid Phase 2 BESTOW Data and Insulin Independence Success

Company Overview

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) is a clinical-stage biotechnology company headquartered in Irvine, California. Founded in 2020, Eledon is developing immunomodulatory therapies aimed at preventing organ and cell transplant rejection, as well as addressing autoimmune and neurodegenerative diseases. Its lead product candidate, tegoprubart, is an anti-CD40L (CD154) monoclonal antibody that targets immune responses associated with graft rejection.

Corporate Structure

According to its LinkedIn profile, Eledon employs between 11 and 50 professionals with expertise in immunology, clinical development, and pharmaceutical manufacturing. The company maintains its research and development facilities in Irvine and collaborates with academic and medical centers, including the University of Chicago Medicine and Massachusetts General Hospital, for investigator-initiated and sponsored clinical trials. Eledon operates under a public governance structure with a board of directors and senior management team led by Chief Executive Officer David-Alexandre C. Gros, M.D., and President and Chief Scientific Officer Steven Perrin, Ph.D.

Immunotherapy by Alex Robertson

Recent Developments and News

• October 29, 2024: In an investigator-initiated trial at UChicago Medicine, two of three type 1 diabetes patients treated with tegoprubart as part of an immunosuppression regimen achieved insulin independence with normal hemoglobin A1C levels. A third patient reduced insulin use by over 60% three days following the transplant.
• November 6, 2025: Eledon presented topline data from its Phase 2 BESTOW trial at the American Society of Nephrology’s Kidney Week 2025. The randomized study compares tegoprubart against standard-of-care tacrolimus regimens in approximately 120 kidney-transplant recipients.
• November 7, 2025: Eledon filed a Form 8-K with the U.S. Securities and Exchange Commission (Accession No. 0001193125-25-270286), reporting items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits).
• Ongoing collaborations: The company has supported xenotransplantation procedures at Massachusetts General Hospital and completed a Phase 2 biomarker study in amyotrophic lateral sclerosis (ALS).

Financial and Strategic Analysis

As of market close on November 6, 2025, Eledon’s share price was $2.00, reflecting a 51.22% decline from the previous trading session on the NASDAQ. Trading volume for the day was 859,304 shares. As a clinical-stage company without approved products, Eledon primarily directs its expenditures toward research and development, clinical trials, and regulatory activities. Its strategy focuses on advancing tegoprubart through Phase 2 and Phase 3 trials in kidney, liver, and islet transplantation while also exploring its potential in autoimmune and neurodegenerative disorders. Collaborating with leading transplant centers and conducting investigator-initiated trials help enhance clinical data, which may support future licensing or co-development agreements.

Market Position and Industry Context

The global demand for organ transplants is projected to more than double over the next decade, leading to a significant need for improved immunosuppression therapies. Since the approval of tacrolimus in 1994, innovation in transplant immunomodulation has been limited. By targeting the CD40 ligand pathway, Eledon aims to provide an alternative approach that may reduce toxicity to grafts and enhance organ durability. The company faces competition from established pharmaceutical firms developing costimulation inhibitors and emerging biotech ventures in xenotransplantation—an area that has garnered increased attention due to organ shortages. Success in pivotal trials and regulatory approvals will be essential for Eledon to establish a commercial position within this specialized field of transplant medicine.

tl;dr

Eledon filed an 8-K on November 7, 2025, and its kidney-transplant Phase 2 BESTOW data were presented on November 6 at ASN Kidney Week. On October 29, 2024, two type 1 diabetes patients achieved insulin independence with tegoprubart-based immunosuppression. The company’s shares closed at $2.00 on November 6, reflecting a 51.22% decline, as trading volume reached 859,304. Upcoming events include full BESTOW results, potential Phase 3 trial initiation, and further investigator-initiated studies.